SCHEMBL4568170

SCHEMBL4568170

Cc1ccc2c(Cc3ccc(C(=O)O)o3)c(C(C)(C)C)[nH]c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.41
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
ESR1 P03372 1/20 0.41
POLB P06746 1/20 0.41
NR4A1 P22736 1/20 0.41
APEX1 P27695 1/20 0.41
RECQL P46063 1/20 0.41
DUSP3 P51452 1/20 0.41
PTPN5 P54829 1/20 0.41
PTPN11 Q06124 1/20 0.41
ESR2 Q92731 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
KMT2A Q03164 2/20 0.40
FBP1 P09467 1/20 0.40
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
LMNA P02545 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568121 0.88 HTT (0.51) ALDH1A1SMN1; SMN2POLBRECQLESR2
SCHEMBL10314447 0.88 EGFR (0.37) EGFRALDH1A1KMT2ARAB9ALMNA
SCHEMBL4568152 0.87 GPR17 (0.44) SMN1; SMN2POLBRAB9ANPC1
SCHEMBL4568143 0.82 MDM4 (0.54) ALDH1A1KMT2AHPGDGFER
SCHEMBL4568168 0.77 MRGPRX4 (0.48) EGFRALDH1A1
SCHEMBL4568113 0.76 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2POLBRAB9ANPC1
SCHEMBL4568169 0.73 ENPP2 (0.41) EGFR
SCHEMBL4568109 0.72 MDM4 (0.56) ALDH1A1SMN1; SMN2POLBKMT2ARAB9A
SCHEMBL4568120 0.70 RAB9A (0.47) SMN1; SMN2RECQLRAB9ANPC1LMNA
SCHEMBL4568138 0.68 TUBB4A (0.49) ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R EGFR 544/4885ALDH1A1 422/4885SMN1; SMN2 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.